Sellas posts positive data from phase 1 trial of lymphoma, acute myeloid leukemia therapy

Jun. 27, 2022 9:02 AM ETSELLAS Life Sciences Group, Inc. (SLS)By: Dania Nadeem, SA News Editor1 Comment

Acute myeloid leukemia (AML).

Md Ariful Islam/iStock via Getty Images

  • Sellas Life Sciences (NASDAQ:SLS) said on Monday no dose-limiting toxicities were observed in lymphoma and acute myeloid leukemia (AML) patients, when treated with its therapy, GFH009, in a Phase 1 trial.
  • (SLS) rose 2.5% before the bell.
  • In the AML group, patients treated at the 22.5 mg dose level experienced no dose limiting toxicities.
  • The company said the AML group had entered the last planned dose level of 30 mg.
  • In the lymphoma group, the 15 mg dose level cohort has completed enrollment and safety assessments for this cohort are currently underway - SLS
  • "Not only does GFH009 appear to be safe at the dose levels studied to date, but we have also observed efficacy in lower dose levels," said Dragan Cicic, Senior Vice President, Clinical Development of Sellas.

Recommended For You

Comments (1)

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.